Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 67, Issue 12, 2006, Pages 1942-1947

  Moeller, Karen E ^a   Shireman, Theresa I ^a   Liskow, Barry I ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DISULFIRAM; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; MOOD STABILIZER; NALTREXONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; ZIPRASIDONE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; FEMALE; GENDER; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; NEUROSIS; PERSONALITY DISORDER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RECURRENCE RISK; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 33845993912     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1215     Document Type: Article

References (27)

1. Hogarty GE. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993;54(3, suppl):18-23
2. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-135
3. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
5. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412
6. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-1749
7. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
8. Bamas ME, Hussain N, Petrides G. Treatment-emergent psychosis with aripiprazole [letter]. J Clin Psychiatry 2005;66:1339
9. DeQuardo JR. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism [letter]? J Clin Psychiatry 2004;65:132-133
10. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19:45-48
11. Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole [letter]. Am J Psychiatry 2004;161:1308
12. Glick ID, Duggal V, Hodulik C. Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol 2006;26:101-103
13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
14. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
15. Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-1577
16. Rabinowitz J, Lichtenberg P, Kaplan Z. et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-269
17. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379-1389
18. Birchwood M, Mason R, MacMillan F, et al. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993;23:387-395
19. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988;152:320-323
20. Roy A, Thompson R. Kennedy S. Depression in chronic schizophrenia. Br J Psychiatry 1983;142:465-470
21. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121
22. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755
23. Regier DA, Farmer ME, Rae DS, et al. Comoibidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518
24. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-347
25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
26. Schwartz AH, Perlman BB, Paris M, et al. Psychiatric diagnoses as reported to Medicaid and as recorded in patient charts. Am J Public Health 1980;70:406-408
27. Rawson NS, Malcolm E, D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc Psychiatry Psychiatr Epidemiol 1997;32:191-199